tradingkey.logo

MDxHealth SA

MDXH
View Detailed Chart
3.530USD
+0.130+3.82%
Close 02/06, 16:00ETQuotes delayed by 15 min
174.73MMarket Cap
LossP/E TTM

MDxHealth SA

3.530
+0.130+3.82%
Intraday
1m
30m
1h
D
W
M
D

Today

+3.82%

5 Days

+0.86%

1 Month

+9.97%

6 Months

+28.36%

Year to Date

-1.12%

1 Year

+92.90%

View Detailed Chart

TradingKey Stock Score of MDxHealth SA

Currency: USD Updated: 2026-02-06

Key Insights

MDxHealth SA's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered undervalued, ranking 91 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 7.04.In the medium term, the stock price is expected to trend down.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

MDxHealth SA's Score

Industry at a Glance

Industry Ranking
91 / 392
Overall Ranking
218 / 4521
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

MDxHealth SA Highlights

StrengthsRisks
MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 143.02% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 90.05M.
Fairly Valued
The company’s latest PE is -3.54, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 22.89M shares, decreasing 5.52% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 202.80K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.58.

Analyst Rating

Based on 6 analysts
Strong Buy
Current Rating
6.040
Target Price
+325.35%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

MDxHealth SA News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

MDxHealth SA Info

MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
Ticker SymbolMDXH
CompanyMDxHealth SA
CEOMr. Michael K. McGarrity
Websitehttps://mdxhealth.com/
KeyAI